12th Mar 2008 07:06
AstraZeneca PLC12 March 2008 TRIAL DATE SET FOR SEROQUEL(R) PATENT LITIGATION LONDON 12 March 2008 - AstraZeneca PLC today announced a trial date has been setfor patent litigation in the US District Court for the District of New Jerseyagainst Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleginginfringement of AstraZeneca's patent as a result of Teva's and Sandoz's filingsof Abbreviated New Drug Applications (ANDAs). The ANDAs seek approval to marketgeneric versions of SEROQUEL(R) (quetiapine fumarate tablets) in the US beforeSEROQUEL's patent expires in 2011. The Court has set a date for trial beginningon 11 August 2008. About AstraZeneca AstraZeneca is a major international healthcare business engaged in theresearch, development, manufacturing and marketing of meaningful prescriptionmedicines and supplier for healthcare services. AstraZeneca is one of theworld's leading pharmaceutical companies with healthcare sales of $29.55 billionand is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory,oncology and infectious disease medicines. In the United States, AstraZeneca isa $13.35 billion dollar healthcare business with 12,200 employees committed toimproving people's lives. AstraZeneca is listed in the Dow Jones SustainabilityIndex (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com. The statements contain herein include forward-looking statements. Although webelieve our expectations are based on reasonable assumptions, anyforward-looking statements, by their very nature, involve risks anduncertainties and may be influenced by factors that could cause actual outcomesand results to be materially different from those predicted. Theforward-looking statements reflect knowledge and information available at thedate of the preparation of this press release and the Company undertakes noobligation to update these forward-looking statements. Important factors thatcould cause actual results to differ materially from those contained inforward-looking statements, certain of which are beyond our control, include,among other things, those risk factors identified in the Company's Annual Reportand Form 20-F Information for 2007. Nothing contained herein should beconstrued as a profit forecast. Media Enquiries:Steve Brown +44 207 304 5033 (24 hours)Chris Sampson +44 20 7304 5130 (24 hours)Neil McCrae +44 207 304 5045 (24 hours) Investor Enquiries UK:Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032Mina Blair +44 20 7304 5084 mob: +44 7718 581021Karl Hard +44 207 304 5322 mob: +44 7789 654364 Investor Enquiries US:Ed Seage +1 302 886 4065 mob: +1 302 373 1361Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043Peter Vozzo (MedImmune) +1 301 398 4358 mob: +1 301 252 7518 ### This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca